Collaborate with us to unlock new therapeutic pathways
Our Cell-Seq™ platform provides unique access to causal disease biology
By partnering with industry leaders, research institutions and academia, we are able to turn genetic discoveries into real-world therapies. Our proprietary Cell-Seq platform gives our partners unique access to modifier genes, enabling them to unlock new therapeutic targets or enhance their pipelines with first-in-class drugs.
- Discover novel, biologically validated targets
- Elucidate mechanisms of action and pathways
- Accelerate drug discovery and development timelines
- Enhance pipeline value with first-in-class opportunities
By collaborating with industry leaders such as Alnylam, Bristol Myers Squibb and Genentech, we combine expertise, innovation, and shared vision to tackle some of the most challenging diseases. Together, we are shaping the future of medicine.
Identifying novel drug targets with Genentech
Advancing the discovery of modifier genes to tackle complex diseases. Scenic utilizes its Cell-Seq™ platform to identify drug targets in multiple therapeutic areas of Genentech’s interest.
Pioneering indication selection with Bristol Myers Squibb
Leveraging Scenic’s Cell-Seq™ platform to unlock new therapeutic pathways for undisclosed targets of Bristol Myers Squibb’s interest. This facilitates indication selection and expansion and accelerates the development of such drug targets.
New drug targets for RNAi therapeutics with Alnylam
Discovering novel targets for RNAi therapeutics with the help of Cell-Seq™. Mapping unexplored biological pathways and connecting these to actionable drug targets forms the basis for new RNAi medicines.
Novel therapeutic targets with Ono Pharmaceutical
Combining Scenic’s unique Cell-Seq™ approach with Ono Pharmaceutical’s know-how to uncover new disease biology and associated drug targets.
Discover how we can
help each other
Want to exploit the power of Scenic’s Cell-Seq platform?
We establish strategic research collaborations to enable novel target identification, pathway elucidation, indication expansion, and exploration of mechanisms of action for both targets and therapies.
Interested in novel, validated drug targets?
We form drug discovery and co-development partnerships around our newly identified targets. Get in touch to explore how we can work together.
Looking for first-in-class small molecule therapeutics?
We are open to partnering and licensing discussions for our small-molecule programs in neuro- and metabolic diseases.